Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | FAAH | O00519 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.54 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3454586 | 0.79 | EPHX2 (0.68) | EPHX2RAB9ANPC1FAAHKMT2A | |
| SCHEMBL19798449 | 0.78 | KMT2A (0.72) | EPHX2RAB9ANPC1FAAHKMT2A | |
| SCHEMBL1420838 | 0.76 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL905264 | 0.76 | P2RX7 (0.54) | EPHX2FAAHKMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL1937671 | 0.76 | NPC1 (0.84) | EPHX2RAB9ANPC1FAAHKMT2A | |
| SCHEMBL6599030 | 0.75 | ALDH1A1 (0.47) | EPHX2RAB9ANPC1FAAHKMT2A | |
| SCHEMBL24209092 | 0.75 | ATM (0.55) | EPHX2RAB9AKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2125504 | 0.75 | ALDH1A1 (0.64) | EPHX2RAB9ANPC1FAAHKMT2A | |
| SCHEMBL15310176 | 0.74 | NPC1 (1.00) | EPHX2RAB9ANPC1FAAHKMT2A | |
| SCHEMBL12932018 | 0.74 | NPC1 (0.94) | EPHX2RAB9ANPC1FAAHKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928137-B2 | Meta-benzamidine derivatives as serine protease inhibitors | TULARIK LIMITED (GB) | 2011-04-19 | — | — | US | disclosed |
| US-20070155790-A1 | Meta-benzamidine derivatives as serine protease inhibitors | LIEBESCHUETZ JOHN W | 2007-07-05 | — | — | US | disclosed |
| US-7220781-B2 | Meta-benzamidine derivatives as serine protease inhibitors | TULARIK LIMITED (GB) | 2007-05-22 | — | — | US | disclosed |
| EP-1009758-B1 | META-BENZAMIDINE DERIVATIVES AS SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2005-06-01 | — | — | EP | disclosed |
| US-20040143018-A1 | Meta-benzamidine derivatives as serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-07-22 | — | — | US | disclosed |
| US-6740682-B2 | TREATMENT OF THROMBOTIC DISEASES, ASTHMA, EMPHYSEMA, CIRRHOSIS, ARTHRITIS, CARCINOMA, MELANOMA, RESTENOIS, ATHEROMA, TRAUMA, SHOCK AND REPERFUSION INJURY. | TULARIK LIMITED (GB) | 2004-05-25 | — | — | US | disclosed |
| US-20020055522-A1 | Meta-benzamidine derivatives as serine protease inhibitors | TULARIK LIMITED (GB) | 2002-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055522-A1 | Meta-benzamidine derivatives as serine protease inhibitors | SERPINE1, PEPD, PRSS1 | EPHX2 2980/4885RAB9A 1305/4885NPC1 1854/4885 |
| US-20070155790-A1 | Meta-benzamidine derivatives as serine protease inhibitors | PEPD, SERPINE1, HPN | EPHX2 2976/4885RAB9A 1562/4885NPC1 2130/4885 |
| US-20040143018-A1 | Meta-benzamidine derivatives as serine protease inhibitors | SERPINE1, PEPD, PRSS1 | EPHX2 2980/4885RAB9A 1305/4885NPC1 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.